News Updates
FDA Authorizes Novel Clinical Trial Exploring Artery-Delivered Stem Cells for Knee Osteoarthritis
University of Miami Miller School of Medicine researchers are preparing to launch an innovative clinical trial that will investigate whether delivering stem cells through arteries supplying the knee can reduce pain and improve function and quality of life in patients with osteoarthritis who have exhausted other nonsurgical treatment options.
Source: University of Miami
Next-generation therapies for osteoarthritis: the evolving role of cell therapy products
This Review discusses recent clinical trial data, mechanistic insights, regulatory considerations, and operational challenges shaping the evolving role of cell therapy products for OA as next-generation candidates to bridge the gap between pharmacological and surgical interventions.
Injectable Self-Healable Conductive Hydrogel/Microsphere Composite Cell Delivery System as a 3D Composite Carrier of Adipose-Derived Stem Cells for Skeletal Muscle Regeneration
Volumetric muscle loss (VML) presents a significant clinical challenge due to the limited regenerative capacity of skeletal muscle. Cell therapy using adipose-derived stem cells (ADSCs) offers a promising alternative to invasive muscle transplantation, but its efficacy is hampered by poor cell retention and survival at the injury site.
Source: ScienceDirect
DNA-Adsorbing Nanozyme Hydrogel Reprograms the Immuno-Oxidative Microenvironment to Support Stem Cell-Based Cartilage Repair in Osteoarthritis
Osteoarthritis (OA) is a prevalent degenerative joint disease, and stem cell therapy is often limited by a hostile joint microenvironment. Excessive reactive oxygen species (ROS) and damage-associated cell-free DNA (cfDNA) cooperatively drive innate immune activation, inflammatory macrophage polarization, and chondrogenic instability, forming an immuno-oxidative barrier to cartilage repair. Here, we developed a bioactive DNA-adsorbing nanozyme hydrogel (MNKB/HA) to remodel this niche and enhance BMSC-mediated cartilage repair.
Source: ScienceDirect
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Aging Frailty: A Systematic Review
Aging frailty is a multifactorial geriatric syndrome characterized by reduced physiological reserve across multiple interrelated systems, leading to increased vulnerability to adverse health outcomes. Mesenchymal stem cells (MSCs) have emerged as a potential therapeutic intervention due to their immunomodulatory and regenerative properties. This systematic review aimed to evaluate the available clinical evidence regarding the safety and efficacy of MSC administration in individuals with aging frailty.
Source: MDPI
Cell Therapy is Reshaping the Landscape of the Orthopedics Field, As Industry Giants are Rushing to Place Bets, with Numerous Phase II/III Pipelines Clustered in this Track.
Cell therapy is expected to provide a fundamental solution to this dilemma. Mesenchymal stem cells (MSCs) are a type of adult stem cells with self-renewal and multi-directional differentiation capabilities, with low immunogenicity. Through paracrine and immunomodulatory mechanisms, they can play roles in tissue injury repair, hematopoietic support, nutritional supply, activation of endogenous stem/progenitor cells, immunoregulation, promotion of angiogenesis, and anti-fibrosis.
Source: European Central Station
Responders vs. Non-Responders to Mesenchymal Stromal Cells in Knee Osteoarthritis: Mechanistic Correlates of Donor Cell and Patient Features
Mesenchymal stromal cell (MSC) injection has afforded heterogeneous outcomes in knee osteoarthritis (KOA). Herein, a framework that dually correlates KOA patient responsiveness with baseline autologous bone marrow-derived MSC(M) donor batch attributes and baseline clinical and biomarker features is provided. Using clinical trial data (NCT02351011), we demonstrated that MSC(M) with increased immunomodulatory potency are more efficacious. Multivariable MSC(M) genes correlated strongly with responder status and 12- and 24-month improvements in Knee Injury and Osteoarthritis Outcome Scores.
Source: Stem Cell Reports













